Clinical study on Ⅲ Stage breast cancer patients treated by neoadjuvant chemotherapy
-
摘要: 目的 进一步探讨新辅助化疗对Ⅲ期乳腺癌的临床疗效及 5年生存率的影响。方法 将手术后的 80例Ⅲ期乳腺癌分为A组、B组。A组为CMF方案化疗 3周期后, 1周内手术, B组为术前未施化疗组。手术均为改良根治术, 术后常规综合治疗。结果 A组 5年生存率 (73% ), 明显高于B组 (2 9% ), 差异具有显著性P <0 .0 5。化疗有效组 5年生存率高于化疗无效组。结论 Ⅲ期乳腺癌有效的术前化疗可提高5年生存率Abstract: Objective To study the effect of neoadjuvant chemotherapy(NACT) on Ⅲ stage breast cancer. Methods Eighty patients were randomized to group A (45patients) and group B (35patients), Group A are treated by CMF for 3 cycles before operations, modify radical operation were adopted. Similarly therapy have been performed on both groups after operations. Results The 5 years survival rate (5 years) of group A is significantly higher than that in group B ( P < 0.05 ). The 5 years of patients who are sensiti...
-
Key words:
- NACT /
- Ⅲ Stage breast cancer /
- 5 years survival rate
-
计量
- 文章访问数: 2986
- HTML全文浏览量: 38
- PDF下载量: 664
下载:
